These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 579063)
21. Persistent increase in striatal dopamine stimulated adenylate cyclase activity persists for more than 6 months but disappears after 1 year following withdrawal from 18 months cis-flupenthixol intake. Murugaiah K; Fleminger S; Theodorou A; Jenner P; Marsden CD Biochem Pharmacol; 1983 Sep; 32(17):2495-9. PubMed ID: 6684429 [TBL] [Abstract][Full Text] [Related]
22. Effects of S (+)-3-phenethyl-PP, a putative dopamine autoreceptors agonist with greater autoreceptor selectivity than 3-PPP enantiomers. Arnt J; Bøgesø KP; Hyttel J; Larsen JJ; Svendsen O Eur J Pharmacol; 1984 Jun; 102(1):91-9. PubMed ID: 6148247 [TBL] [Abstract][Full Text] [Related]
23. Is dopamine antagonism a requisite of neuroleptic activity? Greenblatt EN; Coupet J; Rauh E; Szucs-Myers VA Arch Int Pharmacodyn Ther; 1980 Nov; 248(1):105-19. PubMed ID: 6111298 [TBL] [Abstract][Full Text] [Related]
25. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? IV. An improved experimental design for measuring the inhibitory effects of neuroleptic drugs on amphetamine-or apomorphine-induced "Cheroing" and "agitation" in rats. Janssen PA; Niemegeers CJ; Schellekens KH; Lenaerts FM Arzneimittelforschung; 1967 Jul; 17(7):841-54. PubMed ID: 5632842 [No Abstract] [Full Text] [Related]
26. The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Ogren SO; Hall H; Köhler C; Magnusson O; Sjöstrand SE Psychopharmacology (Berl); 1986; 90(3):287-94. PubMed ID: 2947255 [TBL] [Abstract][Full Text] [Related]
27. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Ogren SO; Hall H; Köhler C; Magnusson O; Lindbom LO; Angeby K; Florvall L Eur J Pharmacol; 1984 Jul; 102(3-4):459-74. PubMed ID: 6149133 [TBL] [Abstract][Full Text] [Related]
28. Differential reversal by scopolamine and THIP of the antistereotypic and cataleptic effects of neuroleptics. Arnt J; Christensen AV Eur J Pharmacol; 1981 Jan; 69(1):107-11. PubMed ID: 6110555 [TBL] [Abstract][Full Text] [Related]
29. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537 [TBL] [Abstract][Full Text] [Related]
30. Role of brain dopamine in the antipsychotic effect of neuroleptics. Evidence from studies of amphetamine-neuroleptic interaction. Randrup A Mod Probl Pharmacopsychiatry; 1970; 5():60-5. PubMed ID: 5527170 [No Abstract] [Full Text] [Related]
31. Behavioural and biochemical alterations in the function of dopamine receptors following repeated administration of L-DOPA to rats. Hall MD; Cooper DR; Fleminger S; Rupniak NM; Jenner P; Marsden CD Neuropharmacology; 1984 May; 23(5):545-53. PubMed ID: 6539859 [TBL] [Abstract][Full Text] [Related]
32. On the interaction between neuroleptics and antiparkinson drugs. Julou L Mod Probl Pharmacopsychiatry; 1970; 5():50-4. PubMed ID: 5527168 [No Abstract] [Full Text] [Related]
33. Methods for evaluation of long acting neuroleptic drugs in animals. Kazdová E; Dlabac A; Metysová J Act Nerv Super (Praha); 1972; 14(2):126-7. PubMed ID: 5064759 [No Abstract] [Full Text] [Related]
34. The pharmacology of penfluridol (R 16341) a new potent and orally long-acting neuroleptic drug. Janssen PA; Niemegeers CJ; Schellekens KH; Lenaerts FM; Verbruggen FJ; Van Nueten JM; Schaper WK Eur J Pharmacol; 1970 Jul; 11(2):139-54. PubMed ID: 5447800 [No Abstract] [Full Text] [Related]
35. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests. Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001 [TBL] [Abstract][Full Text] [Related]
36. Long-term trial of fluphenazine decanoate and flupenthixol decanoate for cataleptic activity and effect on motor activity in rats. Chandra O; Bernard J; Matussek N Arzneimittelforschung; 1974 Nov; 24(11):1821-4. PubMed ID: 4480057 [No Abstract] [Full Text] [Related]
37. The central nervous system pharmacology of an anti-emetic dihydroindolone derivative. Holmes SW; Gylys JA Arzneimittelforschung; 1973 Sep; 23(9):1314-8. PubMed ID: 4204318 [No Abstract] [Full Text] [Related]
38. Neuropharmacological profile of MD 790501, a new benzamide derivative. Jalfre M; Bucher B; Dorme N; Mocquet G; Porsolt RD Arch Int Pharmacodyn Ther; 1983 Aug; 264(2):232-56. PubMed ID: 6139097 [TBL] [Abstract][Full Text] [Related]
39. The selective dopamine antagonist properties of BRL 34778: a novel substituted benzamide. Brown F; Campbell W; Clark MS; Graves DS; Hadley MS; Hatcher J; Mitchell P; Needham P; Riley G; Semple J Psychopharmacology (Berl); 1988; 94(3):350-8. PubMed ID: 3128811 [TBL] [Abstract][Full Text] [Related]
40. Neurophysiological substrates of the pharmacological criteria for neuroleptics. Stille G Mod Probl Pharmacopsychiatry; 1970; 5():56-60. PubMed ID: 5527169 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]